Endocrine Responsive Her2 Negative Early Breast Cancer clinical trials

Explore recruiting endocrine responsive her2 negative early breast cancer clinical trials.

Recruiting endocrine responsive her2 negative early breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Endocrine Responsive Her2 Negative Early Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Endocrine Responsive Her2 Negative Early Breast Cancer trials by city

Endocrine Responsive Her2 Negative Early Breast Cancer in Toronto Endocrine Responsive Her2 Negative Early Breast Cancer in Vancouver Endocrine Responsive Her2 Negative Early Breast Cancer in Montreal Endocrine Responsive Her2 Negative Early Breast Cancer in Calgary Endocrine Responsive Her2 Negative Early Breast Cancer in Edmonton Endocrine Responsive Her2 Negative Early Breast Cancer in Ottawa Endocrine Responsive Her2 Negative Early Breast Cancer in Winnipeg Endocrine Responsive Her2 Negative Early Breast Cancer in Quebec City Endocrine Responsive Her2 Negative Early Breast Cancer in Hamilton Endocrine Responsive Her2 Negative Early Breast Cancer in Kitchener Endocrine Responsive Her2 Negative Early Breast Cancer in London Endocrine Responsive Her2 Negative Early Breast Cancer in Halifax Endocrine Responsive Her2 Negative Early Breast Cancer in New York Endocrine Responsive Her2 Negative Early Breast Cancer in Los Angeles Endocrine Responsive Her2 Negative Early Breast Cancer in Chicago Endocrine Responsive Her2 Negative Early Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease